$XBI $89.83 | +0.03%
Covid Updates
$NVAX +2.1% Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial. source
$VLON -6.0% Vallon Pharmaceuticals Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19. source
$ADMP +3.3% Adamis Pharmaceuticals’ Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations. source
Pipeline Updates
$KALV -0.1% KalVista Pharmaceuticals Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief From HAE Attacks in Patients. source
$BCLI +0.3% BrainStorm Cell Therapeutics Abstract Selected as Late-Breaking Presentation at the 2022 MDA Clinical & Scientific Conference. source
$ZYNE -2.2% Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X Syndrome. source
$DSGN +0.3% Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia . source
$EDIT +1.3% Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference. source
$NTLA +2.6% Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein. source
$AKTX +3.9% Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes of U.S. Army Trauma Patients in Iraq and the Therapeutic Potential of Nomacopan for Treatment of Trauma. source
$NERV +3.6% Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin. source
$BPMC -2.6% Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies. source
$PLRX -7.1% Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-β Signaling in Healthy Volunteers. source
$SEEL 0% Seelos Therapeutics Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform. source
$ACIU -1.2% AC Immune to Present at the AD/PD™ 2022 New Clinical and Preclinical Data for Alpha-Synuclein, Abeta and TDP-43 Programs. source
$HUMA +5.1% Humacyte Announces Publication of Positive Long-Term Follow-Up Data from Phase 2 Trial of HAV™ for Hemodialysis. source
$IFRX -11.6% InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa. source
$APTX -3.5% Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia. source
$LYRA -5.4% Lyra Therapeutics Announces First Patient Dosed in Pivotal ENLIGHTEN I Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients. source
$SPPI -4.4% Spectrum Pharmaceuticals Announces an Oral Poziotinib Presentation at the Upcoming ESMO TAT 2022 Virtual Meeting. source
$ZYNE -2.2% Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome. source
$MNOV -0.8% MediciNova Announces MN-166 (ibudilast) Identified as Potential Beneficial Pharmacotherapy for Treatment of Degenerative Cervical Myelopathy in Global Spine Journal. source
$EVLO -8.4% Durable and Deepening Clinical Responses Observed in Post-Treatment Period of Evelo Bioscience’s Phase 2 Clinical Trial of Oral EDP1815 in Psoriasis. source
$CYAD -17.1% Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial. source
$PLX +0.9% Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease. source
$AMYT -14.2% Amryt Receives Complete Response Letter from the FDA for Oleogel-S10 NDA. source
Business Updates
$SLS +3.0% SELLAS Life Sciences Announces Final Court Approval of Settlement of Securities Litigation. source
$TNXP +5.7% Tonix Pharmaceuticals Announces Research Agreement with the French National Institute of Health and Medical Research (Inserm) to Study the Mechanism of Oxytocin-Mediated Improvement of Eating Behaviors in Prader-Willi Mice. source
$ABUS -1.8% Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna. source
Posted by FS/HC
Bình luận